Long-term follow-up of the original interferon-β1b trial in multiple sclerosis: Design and lessons from a 16-year observational study

Clinical Therapeutics

Volumn 31, Issue 8, 2009, Pages 1724-1736

  Ebers, George C ^a   Reder, Anthony T ^b   Traboulsee, Anthony ^c   Li, David ^d   Langdon, Dawn ^e   Goodin, Douglas S ^f   Wolf, Christian ^g   Beckmann, Karola ^h   Konieczny, Andreas ^h  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF CHICAGO   (United States)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^d VANCOUVER GENERAL HOSPITAL   (Canada)

^e UNIVERSITY OF LONDON   (United Kingdom)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g UCB PHARMA   (Belgium)

^h BAYER PHARMA AG   (Germany)

Author keywords

ascertainment; interferon 1b; long term follow up; multiple sclerosis; study design

Indexed keywords

INTERFERON BETA SERINE;

ARTICLE; CHRONIC DISEASE; CLINICAL EVALUATION; FEMALE; FOLLOW UP; HUMAN; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; METHODOLOGY; MULTIPLE SCLEROSIS; NEUROPSYCHOLOGICAL TEST; NUCLEAR MAGNETIC RESONANCE IMAGING; OBSERVATIONAL STUDY; PATIENT ASSESSMENT; PATIENT IDENTIFICATION; REFUSAL TO PARTICIPATE; VALIDATION STUDY;

ADJUVANTS, IMMUNOLOGIC; ADULT; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTERFERON-BETA; MALE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PATIENT DROPOUTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RETROSPECTIVE STUDIES; VALIDATION STUDIES AS TOPIC; YOUNG ADULT;

EID: 72149122640     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2009.08.003     Document Type: Article

References (27)

1. In: Paty D.W., and Ebers G.C. (Eds). Multiple Sclerosis (1998), F.A. Davis, Philadelphia, Pa
2. Weinshenker B.G., Bass B., Rice G.P., et al. The natural history of multiple sclerosis: A geographically based study. I. Clinical course and disability. Brain. 112 (1989) 133-146
3. Runmarker B., Andersson C., Odén A., and Andersen O. Prediction of outcome in multiple sclerosis based on multivariate models. J Neurol. 241 (1994) 597-604
4. Ebers G.C., Heigenhauser L., Daumer M., et al. Disability as an outcome in MS clinical trials. Neurology 71 (2008) 624-631
5. Daumer M., Neuhaus A., Morrissey S., et al. MRI as an outcome in multiple sclerosis clinical trials. Neurology 72 (2009) 705-711
6. Orton S.M., Herrera B.M., Yee I.M., et al. Sex ratio of multiple sclerosis in Canada: A longitudinal study. Lancet Neurol. 5 (2006) 932-936
7. The IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 43 (1993) 655-661
8. Paty D.W., Li D.K., and the UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 43 (1993) 662-667
9. The IFNB Multiple Sclerosis Study Group, and The University of British Columbia MS/MRI Analysis Group. Inter-feron beta-1b in the treatment of multiple sclerosis: Final outcome of the randomized controlled trial. Neurology 45 (1995) 1277-1285
10. Lechner-Scott J., Kappos L., Hofman M., et al. Can the Expanded Disability Status Scale be assessed by telephone?. Mult Scler. 9 (2003) 154-159
11. Kremenchutzky M., Rice G.P., Baskerville J., et al. The natural history of multiple sclerosis: A geographically based study 9: Observations on the progressive phase of the disease. Brain 129 (2006) 584-594
12. Cutter G.R., Baier M.L., Rudick R.A., et al. Development of a multiple sclerosis functional composite as a clinical trial outcome measure. Brain 122 (1999) 871-882
13. Kurtzke J.F. Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS). Neurology 33 (1983) 1444-1452
14. Benedict R.H., Fischer J.S., Archibald C.J., et al. Minimal neuropsychological assessment of MS patients: A consensus approach. Clin Neuropsychol 16 (2002) 381-397
15. The EuroQol Group. EuroQol-a new facility for the measurement of health-related quality of life. Health Policy. 16 (1990) 199-208
16. Cella D.F., Dineen K., Arnason B., et al. Validation of the functional assessment of multiple sclerosis quality of life instrument. Neurology 47 (1996) 129-139
17. Zigmond A.S., and Snaith R.P. The hospital anxiety and depression scale. Acta Psychiatr Scand. 67 (1983) 361-370
18. Henriksson F., Fredrikson S., Masterman T., and Jönsson B. Costs, quality of life and disease severity in multiple sclerosis: A cross-sectional study in Sweden. Eur J Neurol. 8 (2001) 27-35
19. Kobelt G., Lindgren P., Parkin D., et al. Costs and quality of life in multiple sclerosis. A cross-sectional observational study in the UK. No. 398. Working Paper Series in Economics and Finance (2000), Stockholm School of Economics, Stockholm, Sweden. http://swopec.hhs.se/hastef/papers/hastef0398.pdf Accessed July 15, 2009
20. Kobelt G., Lindgren P., Smala A., and Jönsson B. Costs and quality of life in multiple sclerosis: A cross-sectional observational study in Germany. No. 399. Working Paper Series in Economics and Finance (2000), Stockholm School of Economics, Stockholm, Sweden. http://ideas.repec.org/p/hhs/hastef/0399.html Accessed July 15, 2009
21. Files J.G., Gray J.L., Do L.T., et al. A novel sensitive and selective bioassay for human type I interferons. J Interferon Cytokine Res. 18 (1998) 1019-1024
22. Kappos L., Traboulsee A., Constantinescu C., et al. Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS. Neurology 67 (2006) 944-953
23. Herndon R.M., Rudick R.A., Munschauer III F.E., et al. Eight-year im-munogenicity and safety of inter-feron beta-1a-Avonex treatment in patients with multiple sclerosis. Mult Scler. 11 (2005) 409-419
24. Ford C.C., Johnson K.P., Lisak R.P., et al., the Copaxone Study Group. A prospective open-label study of glatiramer acetate: Over a decade of continuous use in multiple sclerosis patients. Mult Scler. 12 (2006) 309-320
25. Rice G.P., Nicolle E., Lesaux J., et al. Long term safety, compliance and evolution of neutralizing antibodies in MS patients treated with interfer- on beta 1b. Mult Scler. 7 Suppl 1 (2001) S54 Abstract P-147
26. al-Shahi R., and Warlow C.P. Ethical review of a multicentre study in Scotland: A weighty problem. J R Coll Physicians Lond. 33 (1999) 549-552
27. Kappos L., Freedman M.S., Polman C.H., et al., the BENEFIT Study Group. Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: A 3-year follow-up analysis of the BENEFIT study. Lancet 370 (2007) 389-397